BlinkLab Limited (BB1) Fair Value & Analysis
Healthcare · AU · Market cap A$94.8M
Fair value as of: Jun 24, 2026
Analysis
BlinkLab Limited (BB1) currently trades at A$0.6250, while our model-based Fair Value estimate is A$0.2600 — implying the stock looks roughly 58.4% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations. The company's application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Perth, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BlinkLab Limited (BB1) undervalued?
What is the fair value of BB1?
What is the quality score of BB1?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.